BiotechTube

LY2228820 + Carboplatin + Placebo + Gemcitabine

Phase 1/2Completed
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Epithelial Ovarian Cancer

Conditions

Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

Trial Timeline

Jul 1, 2012 → May 11, 2018

NCT ID
NCT01663857

About LY2228820 + Carboplatin + Placebo + Gemcitabine

LY2228820 + Carboplatin + Placebo + Gemcitabine is a phase 1/2 stage product being developed by Eli Lilly for Epithelial Ovarian Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01663857. Target conditions include Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer.

What happened to similar drugs?

4 of 13 similar drugs in Epithelial Ovarian Cancer were approved

Approved (4) Terminated (1) Active (9)
🔄Mirvetuximab Soravtansine + Paclitaxel + Topotecan + Pegylated liposomal doxorubicinAbbViePhase 3
🔄AZD5335 + Mirvetuximab Soravtansine (MIRV) + Paclitaxel + Pegylated liposomal Doxorubicin (PLD) + TopotecanAstraZenecaPhase 3
🔄Active Comparator: Olaparib tablets + PlaceboAstraZenecaPhase 3
✅Olaparib + BevacizumabAstraZenecaApproved
🔄Comparator: Quadrivalent Human Papillomavirus (HPV) vaccine + Comparator: Menactra™ (Concomitant) + Comparator: Adacel™ (Concomitant) + Comparator: Menactra™ (Non-concomitant) + Comparator: Adacel™MerckPhase 3
🔄Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Current Manufacturing Facility (CMF) + Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Future Manufacturing Facility (FMF) + Comparator: REPEVAX™ (Concomitant) + Comparator: REPEVAX™ (Non-Concomitant)MerckPhase 3
🔄V501MerckPhase 3

Hype Score Breakdown

Clinical
9
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01663857Phase 1/2Completed

Competing Products

20 competing products in Epithelial Ovarian Cancer

See all competitors
ProductCompanyStageHype Score
Doxorubicin Hydrochloride Liposome InjectionDr. Reddy's LaboratoriesPhase 1
26
gemcitabine + carboplatin + paclitaxelEli LillyPhase 2
35
PemetrexedEli LillyPhase 2
35
DE-105 ophthalmic solution + DE-105 ophthalmic solution + Placebo ophthalmic solutionSanten PharmaceuticalPhase 2
35
Mirvetuximab Soravtansine + Paclitaxel + Topotecan + Pegylated liposomal doxorubicinAbbViePhase 3
40
Carboplatin + Mirvetuximab Soravtansine + BevacizumabAbbViePhase 2
42
Mirvetuximab SoravtansineAbbViePhase 2
42
AZD5335 + Mirvetuximab Soravtansine (MIRV) + Paclitaxel + Pegylated liposomal Doxorubicin (PLD) + TopotecanAstraZenecaPhase 3
47
AvelumabAstraZenecaPhase 2
27
Active Comparator: Olaparib tablets + PlaceboAstraZenecaPhase 3
40
Olaparib + carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weeklyAstraZenecaPhase 2
31
Olaparib + BevacizumabAstraZenecaApproved
47
Comparator: Quadrivalent Human Papillomavirus (HPV) vaccine + Comparator: Menactra™ (Concomitant) + Comparator: Adacel™ (Concomitant) + Comparator: Menactra™ (Non-concomitant) + Comparator: Adacel™MerckPhase 3
40
PembrolizumabMerckPhase 2
42
MK-1775 and carboplatinMerckPhase 2
35
GardasilMerckPhase 1
29
NG-350A plus PembrolizumabMerckPhase 1
29
Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Current Manufacturing Facility (CMF) + Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Future Manufacturing Facility (FMF) + Comparator: REPEVAX™ (Concomitant) + Comparator: REPEVAX™ (Non-Concomitant)MerckPhase 3
40
V501MerckPhase 3
40
9-valent HPV vaccinationMerckPhase 2
42